I own ONCS, but it's far from a sure thing. Trials results have been positive so far but that's no guarantee of future successes (plenty examples of that scenario).
ONCS is a spec biotech company, plain and simple.
Don't fool yourself into thinking that there are no negatives surrounding the company. If there wasn't, it wouldn't be selling at 50 cents.
The agency is asking a court to throw out the agreement between the companies.
AndroGel is AbbVie's second-best selling drug. The company reported $1.04 billion in revenue from AndroGel in 2013, but that was a 10-percent drop from the previous year.
AbbVie said its lawsuits were appropriate and that the settlement agreements were legal and in the best interests of both companies. Teva didn't immediately respond to a request for comment.
You forgot to add the rest of the article.
Ontop stated two weeks ago, the stock (then trading in the low 40s) would be in the mid to low 30s the following week. So that refutes your statement that he has been correct every time.
Also, I think it's funny how he (Ontop) disappears when the stock runs then reappears when it pulls back. (Same goes for some of the pumpers.)
I agree, it's always nice to book profits.
All these monthly, weekly, daily, hourly predictions are worthless.
You have an investment that went up 20-30X and you haven't sold a share?
It's been a rough 6 months, bought ECYT instead of ITMN (which I was considering at the time) then turnaround and bought some EXEL. Big haircuts with those two.
I recently bought a little FLML. We'll see where that goes.
Too much chasing.
I don't remember him stating that he owned EXEL, only that it's was cheap at the time (now it's cheaper).
He did state that he sold everything 2 weeks and moved into cash, then changed his mind after an hour and has been booking gains ever since.
Just think of the posts as entertainment.
If people invested their life savings in a spec biotech stock then shame on them.
As for the posters who are relishing in the trial's failure, hindsight's 20/20.
The risk with the HEPLISAV trial isn't inferiority, it's AEs.
However, I do agree, phase III success does not guarantee commercial success.